CHPA: Arizona passes DXM age-restriction law
WASHINGTON — The Consumer Healthcare Products Association on Wednesday commended Arizona Governor Jan Brewer for signing HB 2086 in to law. H.B. 2086, sponsored by Representative Heather Carter, prohibits minors from purchasing over-the-counter cough medicines containing dextromethorphan without a prescription.
“The makers of over-the-counter medicines want to thank Governor Brewer, Representative Carter, and the Arizona legislature for taking a major step to address teen cough medicine abuse,” stated CHPA president and CEO Scott Melville.
“The bill addresses the key issue of access — without access to these drugs — we can reduce the number of teens abusing these medicines," Carter said. "Our goal is to provide parents with the resources to keep their families safe and to raise awareness among other community stakeholders. We hope this accomplishment in Arizona will help generate further support for a national law.”
Upon enactment of this bill, Arizona will be the fifth state to place an age-18 restriction on DXM sales. Louisiana and New Jersey are currently exploring similar legislation.
Walgreens and the National Urban League launch 2014 Walgreens Way to Well Health Tour
DEERFIELD, Ill. — Walgreens and the National Urban League on Thursday announced the launch of the 2014 Walgreens Way to Well Health Tour. For eight years, Walgreens and the NUL have conducted the community outreach program dedicated to providing free preventive and early detection health services to urban and minority communities across the country. Now through December, Walgreens will use the tour to provide free health tests, assessments, education and consulting services.
The tour will provide resources and incentives to help participants continue on their way to healthier living. For example, Walgreens will introduce visitors to various aspects of Walgreens Balance Rewards for healthy choices, which is one of the first retail rewards programs that not only issues rewards for purchases, but also for healthy choices such as walking, running, weight management and testing blood pressure and blood glucose.
The health tour’s bundle of free health tests and risk assessments is designed to provide participants with personal health insights that may indicate symptoms and potential risks for cancer, heart disease and diabetes. Tests include total cholesterol, glucose, blood pressure, body mass index, body composition, skeletal muscle, resting metabolism, visceral fat, real body age and body weight. Collectively the health tests, valued at over $100, are administered to adults age 18 years and older by certified wellness staff and can be completed in approximately 20 minutes. Afterward, participants consult with a Walgreens pharmacist or certified wellness staff about his or her results. This is a free service; insurance will not be billed.
Visitors of the tour also will receive tutorials on how to use fitness devices and digital applications to help track their personal health and fitness goals. Devices will be displayed and visitors will have the opportunity to learn how to use the devices and how to sync them to auto-log their healthy activities into their Balance Rewards account.
The Walgreens Way to Well Health Tour with NUL is one of the charitable programs that is part of the Walgreens Way to Well Commitment, which began in 2011 as a four-year, $100 million initiative to improve the everyday health of Americans nationwide. The initiative also is dedicated to providing accessible, affordable resources for prevention and early detection of chronic diseases like heart disease, cancer and diabetes.
For the past eight years, Walgreens and the NUL have partnered together on the community outreach program and since the tour’s inception, Walgreens has financially contributed nearly $2 million to the NUL for the continued use in providing health services and awareness to their Urban League affiliates across the country. In seven years, the tour has administered more than half a million health tests valued at $11.9 million to communities throughout the United States.
AstraZeneca rejects Pfizer’s $106 billion bid
LONDON — AstraZeneca rejected Pfizer’s $106 billion bid for the company Friday morning.
"The financial and other terms described in the proposal are inadequate, substantially undervalue AstraZeneca and are not a basis on which to engage with Pfizer" the company stated. "The large proportion of the consideration payable in Pfizer shares and the tax-driven inversion structure remain unchanged. Accordingly, the board has rejected the proposal."
“AstraZeneca continues to invest significantly in research, development and manufacturing in the United Kingdom, Sweden and the United States," said Leif Johansson, AstraZeneca chairman. "We are showing strong momentum as an independent company, in particular with our exciting, rapidly progressing pipeline, which the board believes will deliver significant value for shareholders. Pfizer’s proposal would dramatically dilute AstraZeneca shareholders’ exposure to our unique pipeline and would create risks around its delivery."